[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634728":3},{"organization":4,"outcomesModule":7,"designInfo":54,"detailedDescription":67,"studyPopulation":53,"armGroups":68,"interventions":87,"overallOfficials":109,"centralContacts":114,"locations":123,"responsibleParty":354,"collaborators":356,"id":396,"slug":397,"hasResults":398,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":398,"sex":404,"minAge":405,"maxAge":53,"enrollmentInfo":406,"targetDuration":53,"studyType":409,"phases":410,"briefSummary":412,"conditions":413,"keywords":422,"overallStatus":426,"whyStopped":53,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":436},{"fullName":5,"class":6},"Oxford University Clinical Research Unit, Vietnam","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":53},[9,13],{"measure":10,"description":11,"timeFrame":12},"Progression to severe dengue\u002Fcritical dengue","In the trial, baseline severity of dengue will be assessed at the start of study participation. Participants will be defined in accordance with our case definitions as having moderate, severe or critical dengue, based on clinical signs and symptoms, laboratory parameters, and if they have evidence of organ failure with or without need for organ support. At hospital discharge or following death, we will capture if the participant had evidence of at least one of:\n\n* Progression to Severe dengue, in a participant with moderate dengue at enrolment,\n* Progression to Critical dengue, in a participant with moderate or severe dengue at enrolment.","between randomization to hospital discharge (average of 5 days)",{"measure":14,"description":15,"timeFrame":16},"All-cause mortality within 30 days","All-cause mortality in any participant. Assessed as dead or alive","Day 30",[18,22,26,29,32,36,39,42,46,50],{"measure":19,"description":20,"timeFrame":21},"Length of hospital stay","Number of days from hospital admission to discharge","At hospital discharge (average of 5 days)",{"measure":23,"description":24,"timeFrame":25},"Lowest recorded platelet count","Lowest recorded platelet count between randomisation and hospital discharge","Between randomisation and hospital discharge (average of 5 days)",{"measure":27,"description":28,"timeFrame":25},"Acute kidney injury","Serum creatinine \\> 3.5 mg\u002FdL or more than double baseline",{"measure":30,"description":31,"timeFrame":25},"Liver involvement","Highest recorded ALT or AST",{"measure":33,"description":34,"timeFrame":35},"Change in ALT\u002FAST","N-acetylcysteine treatment comparison only. Fold change in ALT or AST","at randomisation, day 2 (if feasible) and day 4 or hospital discharge (average on day 5) if sooner",{"measure":37,"description":38,"timeFrame":25},"Highest bilirubin","N-acetylcysteine treatment comparison only. Highest recorded bilirubin",{"measure":40,"description":41,"timeFrame":25},"Highest INR","N-acetylcysteine treatment comparison only. Highest recorded INR",{"measure":43,"description":44,"timeFrame":45},"Safety reporting: Suspected Severe Adverse Reactions","Suspected serious adverse reactions (SSARs) excluding primary outcomes","During hospital stay (average of 5 days) and at day 30 follow up",{"measure":47,"description":48,"timeFrame":49},"Quality of live assessment using EQ-5D-5L value index","The EQ-5D-5L (EuroQoL \\[European Quality of Life\\] 5-Dimension 5-Level) is a standardized measure of health-related quality of life assessing five domains: mobility, self-care, usual activities, pain\u002Fdiscomfort, and anxiety\u002Fdepression.\n\nEach domain is self-reported by the respondent and rated on five levels of severity, ranging from \"no problems\" (level 1) to \"extreme problems\u002Funable\" (level 5).\n\nResponses across the five domains define a health state, which is converted into a single index (utility) score using population-based value sets. This index score typically ranges from values below 0 (health states considered worse than death) to 1 (perfect health).","at day 30 follow up",{"measure":51,"description":52,"timeFrame":49},"Quality of live assessment using EQ-Visual Analogue Scale (VAS)","This is a self-rated measure of overall health. Respondent indicate their current health status on a vertical scale from 0 to 100. A score of 0 represents \"the worst health you can imagine\" and 100 represents \"the best health you can imagine\". This measure captures the respondent's subjective assessment of their overall health on the day of evaluation. When this assessment done remotely by telephone, the rating is approximated verbally by the respondent using the 0 to 100 numeric scale.",null,{"allocation":55,"interventionModel":56,"interventionModelDescription":57,"primaryPurpose":58,"observationalModel":53,"timePerspective":53,"maskingInfo":59},"RANDOMIZED","FACTORIAL","This multi-site, phase 3, randomised, clinical trial will evaluate therapeutic agents in patients hospitalised with moderate or severe dengue virus infection. The trial will employ partial factorial randomisation. Participants who provide informed consent will be entered into one or more randomisations, depending on eligibility for each intervention, clinician discretion, and availability of the treatment at the study site. Patients are randomised to Baricitinib versus placebo (Comparison A) and\u002For Dexamethasone versus placebo (Comparison B) depending on eligibility. Participants who are ineligible for one intervention are randomized only to the other intervention. In addition, participants with evidence of liver involvement undergo a second, independent randomisation to receive N-acetylcysteine or standard of care (Comparison C). This second randomisation may occur at any time during admission, when the patient is first noted to fulfil the eligibility criteria during the main trial.","TREATMENT",{"masking":60,"maskingDescription":61,"whoMasked":62},"QUADRUPLE","For placebo-matched agents, the participant, care provider, investigator and outcomes assessor will all be masked. Currently, this includes baricitinib and dexamethasone.\n\nThe N-acetylcysteine arm is open-label with no masking; there will be no matched placebo. Treatment with N-acetylcysteine will be compared to standard care.",[63,64,65,66],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","This multi-site, factorial randomised, platform clinical trial will evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. The primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.\n\nThe trial will employ partial factorial randomization. Participants who provide informed consent will be entered into one or more randomisations, depending on eligibility for each intervention, clinician discretion, and availability of the treatment at the study site. For each intervention, eligible participants will be randomised in a 1:1 ratio to receive either the active intervention or the corresponding control (either matched placebo or usual care, depending on the intervention). Participants who are ineligible for a specific treatment comparison may still enter other treatment comparisons within the trial.\n\nOutcomes are described in more detail in the outcome section below. Participants will be followed up until death\u002Fday 30 after randomisation (whichever is sooner) to monitor for primary, secondary and safety outcomes. Participants who have been discharged from hospital alive before day 30 will have a final assessment conducted by telephone at least 30 days after randomisation.\n\nPatients will be additionally consented for collection of a blood sample, taken and stored as a dried blood spot, for analyses in genetic studies and other research.",[69,76,81],{"label":70,"type":71,"description":72,"interventionNames":73},"Comparison A: Baricitinib versus placebo","EXPERIMENTAL","Participants eligible for baricitinib may be randomized to baricitinib or matched placebo.",[74,75],"Drug: Placebo","Drug: Baricitinib",{"label":77,"type":71,"description":78,"interventionNames":79},"Comparison B: Dexamethasone versus Placebo","Participants eligible for dexamethasone may be randomized to dexamethasone or matched placebo.",[74,80],"Drug: Dexamethasone",{"label":82,"type":71,"description":83,"interventionNames":84},"Comparison C: N-acetylcysteine versus standard of care","Patients with liver involvement (ALT or AST \\>400 IU\u002FL) during hospital admission may be randomised to N-acetylcysteine or standard of care.",[85,86],"Drug: N-Acetylcysteine","Other: Standard of care",[88,93,97,101,105],{"type":89,"name":90,"description":91,"armGroupLabels":92,"otherNames":53},"DRUG","Placebo","Placebo matched to baricitinib\u002Fdexamethasone in form, dose, frequency and duration.",[70,77],{"type":89,"name":94,"description":95,"armGroupLabels":96,"otherNames":53},"Dexamethasone","Dexamethasone is a corticosteroid. Form: tablet or intravenous preparation.\n\nDose:\n\nAged ≥ 12 years: 6mg once daily.\n\nAged 5 - 11 years by weight:\n\n* 10kg to \\\u003C20 kg: 2mg once daily,\n* 20kg to \\\u003C30 kg: 4mg once daily,\n* 30kg: 6mg once daily.\n\nDuration: 4 days, or until discharge if this happens before.",[77],{"type":89,"name":98,"description":99,"armGroupLabels":100,"otherNames":53},"N-Acetylcysteine","N-acetylcysteine acts to protect the liver. It functions as a glutathione precursor and antioxidant.\n\nDose: 100mg\u002Fkg\u002Fday, by continuous infusion over 24 hours in glucose 5% (preferred) or sodium chloride 0.9%.\n\nDuration: 4 days, or until hospital discharge if sooner.",[82],{"type":6,"name":102,"description":103,"armGroupLabels":104,"otherNames":53},"Standard of care","Standard of care as per local site guidelines",[82],{"type":89,"name":106,"description":107,"armGroupLabels":108,"otherNames":53},"Baricitinib","Baricitinib is an inhibitor of Janus Kinase (JAK) 1 \\& 2, and Numb associated kinase (NAK).\n\nForm: tablet.\n\nDose:\n\nAged ≥ 12 years: 4mg once daily, Aged 5 - 11 years: 2mg once daily. - Renal adjustment of dose:\n\nAdults:\n\neGFR ≥30 and \\\u003C60 mL\u002Fmin\u002F1.73m2: 2mg once daily, eGFR ≥15 and \\\u003C30 mL\u002Fmin\u002F1.73m2: 2mg on alternate days.\n\nChildren:\n\neGFR ≥30 and \\\u003C60mL\u002Fmin\u002F1.73m2: 2mg on alternate days\n\n\\- Dose should be halved in patients also taking probenecid Duration: 4 days, or less if the patient is discharged before this time.",[70],[110],{"name":111,"affiliation":112,"role":113},"Sophie Yacoub, MD., PhD.","University of Oxford, UK","PRINCIPAL_INVESTIGATOR",[115,119],{"name":116,"role":117,"phone":53,"phoneExt":53,"email":118},"Mr. Samuel Paul","CONTACT","den-host@ndm.ox.ac.uk",{"name":120,"role":117,"phone":121,"phoneExt":53,"email":122},"OUCRU-CTU","+84283924193","CTU-Wthics@oucru.org",[124,139,154,161,175,189,201,209,223,237,251,265,272,286,300,316,326,344],{"facility":125,"status":53,"city":126,"state":53,"zip":53,"country":127,"countryCode":128,"cosmosGeoPoint":129,"geoPoint":134,"contacts":135},"Chittagong Medical College Hospital","Chittagong","Bangladesh","BD",{"type":130,"coordinates":131},"Point",[132,133],91.83168,22.3384,{"lat":133,"lon":132},[136],{"name":137,"role":117,"phone":53,"phoneExt":53,"email":138},"Aniruddha Ghose, Prof","anrdghs@yahoo.com",{"facility":140,"status":53,"city":141,"state":53,"zip":53,"country":127,"countryCode":128,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Dhaka Medical College & Hospital","Dhaka",{"type":130,"coordinates":143},[144,145],90.40744,23.7104,{"lat":145,"lon":144},[148,151],{"name":149,"role":117,"phone":53,"phoneExt":53,"email":150},"Md. Jobayer Chisti, MD","chisti@icddrb.org,",{"name":152,"role":117,"phone":53,"phoneExt":53,"email":153},"Lubaba Shahrin, MD","lubabashahrin@icddrb.org",{"facility":155,"status":53,"city":141,"state":53,"zip":53,"country":127,"countryCode":128,"cosmosGeoPoint":156,"geoPoint":158,"contacts":159},"Dhaka North City Corporation Hospital",{"type":130,"coordinates":157},[144,145],{"lat":145,"lon":144},[160],{"name":152,"role":117,"phone":53,"phoneExt":53,"email":153},{"facility":162,"status":53,"city":163,"state":53,"zip":53,"country":164,"countryCode":165,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Instituto de Infectologia Emílio Ribas","São Paulo","Brazil","BR",{"type":130,"coordinates":167},[168,169],-46.63611,-23.5475,{"lat":169,"lon":168},[172],{"name":173,"role":117,"phone":53,"phoneExt":53,"email":174},"Claudia Figueiredo Mello, MD","claudia.mello@emilioribas.sp.gov.br",{"facility":176,"status":53,"city":177,"state":53,"zip":53,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"Centro de Atención y Diagnóstico de Enfermedades Infecciosas","Bucaramanga","Colombia","CO",{"type":130,"coordinates":181},[182,183],-73.11895,7.125,{"lat":183,"lon":182},[186],{"name":187,"role":117,"phone":53,"phoneExt":53,"email":188},"Luis A Villar, MD","direccioninvestigacion@cdi.net.co",{"facility":190,"status":53,"city":191,"state":53,"zip":53,"country":178,"countryCode":179,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Fundación Valle del Lili","Cali",{"type":130,"coordinates":193},[194,195],-76.5199,3.43054,{"lat":195,"lon":194},[198],{"name":199,"role":117,"phone":53,"phoneExt":53,"email":200},"Carlos Cotes, MD","centrodeinvestigaciones@fvl.org.co",{"facility":202,"status":53,"city":203,"state":53,"zip":53,"country":178,"countryCode":179,"cosmosGeoPoint":204,"geoPoint":208,"contacts":53},"Hospital Universitario Erasmo Meoz","Cúcuta",{"type":130,"coordinates":205},[206,207],-72.5049,7.90745,{"lat":207,"lon":206},{"facility":210,"status":53,"city":211,"state":53,"zip":53,"country":212,"countryCode":213,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Universitas Sumatera Utara","Medan","Indonesia","ID",{"type":130,"coordinates":215},[216,217],98.66667,3.58333,{"lat":217,"lon":216},[220],{"name":221,"role":117,"phone":53,"phoneExt":53,"email":222},"Inke Nadia Diniyanti Lubis, MD","inke.nadia@usu.ac.id",{"facility":224,"status":53,"city":225,"state":53,"zip":53,"country":226,"countryCode":227,"cosmosGeoPoint":228,"geoPoint":232,"contacts":233},"Hospital Queen Elizabeth II, Sabah","Kota Kinabalu","Malaysia","MY",{"type":130,"coordinates":229},[230,231],116.0724,5.9749,{"lat":231,"lon":230},[234],{"name":235,"role":117,"phone":53,"phoneExt":53,"email":236},"Giri Rajaharam, MD","gsrajahram@gmail.com",{"facility":238,"status":53,"city":239,"state":53,"zip":53,"country":226,"countryCode":227,"cosmosGeoPoint":240,"geoPoint":244,"contacts":245},"University Malaya Medical Centre","Kuala Lumpur",{"type":130,"coordinates":241},[242,243],101.68653,3.1412,{"lat":243,"lon":242},[246,248],{"name":247,"role":117,"phone":53,"phoneExt":53,"email":53},"Mohad Shahnaz Hasan, MD",{"name":249,"role":117,"phone":53,"phoneExt":53,"email":250},"Ong Hang-Cheng, MD","ong.hc@ummc.edu.my",{"facility":252,"status":53,"city":253,"state":53,"zip":53,"country":254,"countryCode":255,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"National Academy of Medical Sciences\u002FBir Hospital","Kathmandu","Nepal","NP",{"type":130,"coordinates":257},[258,259],85.3206,27.70169,{"lat":259,"lon":258},[262],{"name":263,"role":117,"phone":53,"phoneExt":53,"email":264},"Sudeep Adhikari, MD","sadhikari@oucru.org",{"facility":266,"status":53,"city":253,"state":53,"zip":53,"country":254,"countryCode":255,"cosmosGeoPoint":267,"geoPoint":269,"contacts":270},"Sukraraj Tropical and Infectious Disease Hospital",{"type":130,"coordinates":268},[258,259],{"lat":259,"lon":258},[271],{"name":263,"role":117,"phone":53,"phoneExt":53,"email":264},{"facility":273,"status":53,"city":274,"state":53,"zip":53,"country":275,"countryCode":276,"cosmosGeoPoint":277,"geoPoint":281,"contacts":282},"Hospital Regional de Loreto","Iquitos","Peru","PE",{"type":130,"coordinates":278},[279,280],-73.2529,-3.74814,{"lat":280,"lon":279},[283],{"name":284,"role":117,"phone":53,"phoneExt":53,"email":285},"Juan Carlos Celis Salinas, MD","gipeit@gmail.com",{"facility":287,"status":53,"city":288,"state":53,"zip":53,"country":289,"countryCode":290,"cosmosGeoPoint":291,"geoPoint":295,"contacts":296},"San Lazaro Hospital","Manila","Philippines","PH",{"type":130,"coordinates":292},[293,294],120.9822,14.6042,{"lat":294,"lon":293},[297],{"name":298,"role":117,"phone":53,"phoneExt":53,"email":299},"Ana Ria Sayo, MD","sayoanaria@gmail.com",{"facility":301,"status":53,"city":302,"state":53,"zip":53,"country":303,"countryCode":304,"cosmosGeoPoint":305,"geoPoint":309,"contacts":310},"Siriraj Hospital, Mahidol University","Bangkok","Thailand","TH",{"type":130,"coordinates":306},[307,308],100.50144,13.75398,{"lat":308,"lon":307},[311,314],{"name":312,"role":117,"phone":53,"phoneExt":53,"email":313},"Nasikarn Angkasekwinai, MD","nasikarn@gmail.com",{"name":315,"role":117,"phone":53,"phoneExt":53,"email":53},"Panisadee Avirutnan, MD",{"facility":317,"status":53,"city":318,"state":53,"zip":53,"country":303,"countryCode":304,"cosmosGeoPoint":319,"geoPoint":323,"contacts":324},"Prince of Songkla University in Southern Thailand","Songkhla",{"type":130,"coordinates":320},[321,322],100.5951,7.19882,{"lat":322,"lon":321},[325],{"name":312,"role":117,"phone":53,"phoneExt":53,"email":313},{"facility":327,"status":53,"city":328,"state":53,"zip":53,"country":329,"countryCode":330,"cosmosGeoPoint":331,"geoPoint":335,"contacts":336},"Hospital for Tropical Diseases","Ho Chi Minh City","Vietnam","VN",{"type":130,"coordinates":332},[333,334],106.62965,10.82302,{"lat":334,"lon":333},[337,339,342],{"name":338,"role":117,"phone":53,"phoneExt":53,"email":53},"Dung Thanh Nguyen, MD",{"name":340,"role":117,"phone":53,"phoneExt":53,"email":341},"Trung Ngoc Truong, MD","drngoctrung2984@gmail.com",{"name":340,"role":343,"phone":53,"phoneExt":53,"email":53},"SUB_INVESTIGATOR",{"facility":345,"status":53,"city":328,"state":53,"zip":53,"country":329,"countryCode":330,"cosmosGeoPoint":346,"geoPoint":348,"contacts":349},"Number 2 Children's Hospital",{"type":130,"coordinates":347},[333,334],{"lat":334,"lon":333},[350,352],{"name":351,"role":117,"phone":53,"phoneExt":53,"email":53},"Tung Huu Trinh, MD",{"name":353,"role":343,"phone":53,"phoneExt":53,"email":53},"Qui Dinh Nguyen, MD",{"type":355,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR",[357,359,362,364,366,368,370,372,374,376,378,380,382,384,386,388,390,392,394],{"name":358,"class":6},"University of Oxford",{"name":360,"class":361},"The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","UNKNOWN",{"name":363,"class":6},"Number 2 Children's Hospital, Ho Chi Minh City",{"name":365,"class":361},"Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal",{"name":367,"class":361},"National Academy of Medical Sciences\u002FBir Hospital, Kathmandu, Nepal",{"name":369,"class":6},"Siriraj Hospital",{"name":371,"class":361},"Prince of Songkla University in Southern Thailand, Thailand",{"name":373,"class":6},"Dhaka Medical College",{"name":375,"class":361},"Chittagong Medical College Hospital, Chittagong, Bangladesh",{"name":377,"class":361},"Centro de Atención y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia",{"name":379,"class":361},"Hospital Universitario Erasmo Meoz, Cucuta, Colombia",{"name":381,"class":361},"Fundación Valle del Lili, Cali, Colombia",{"name":383,"class":361},"Hospital Regional de Loreto, Iquitos, Peru",{"name":385,"class":361},"Instituto de Infectologia Emílio Ribas, São Paulo, Brazil",{"name":387,"class":361},"Universitas Sumatera Utara, Medan, Indonesia",{"name":389,"class":361},"Airlangga University (UNAIR), Indonesia",{"name":391,"class":361},"University Malaya Medical Centre, Malaysia",{"name":393,"class":361},"Hospital Queen Elizabeth II, Malaysia",{"name":395,"class":361},"San Lazaro Hospital (SLH-NU), Manila, Philippines","100634728","phase-3-therapeutics-for-moderate-and-severe-dengue-100634728",false,"NCT07543458","Therapeutics for Moderate and Severe Dengue","A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)","DEN-HOST","Inclusion Criteria:\n\n* Age ≥5 years\n* Decision to hospitalise\n* Clinical diagnosis of dengue\n* Participants must also have at least one of the following:\n\n  1. Severe abdominal pain or tenderness\n  2. Vomiting more than 3 times in the past 24 hours\n  3. Pleural effusion or ascites on clinical or radiological examination\n  4. Absolute haematocrit \\>50%\n  5. 15% increase in haematocrit compared with a baseline sample (defined as the first sample taken during the current illness)\n  6. Absolute platelet count \\\u003C50 × 10⁹\u002FL\n  7. Absolute platelet count \\\u003C100 × 10⁹\u002FL AND a drop \\>50 × 10⁹\u002FL in the past 32 hours\n  8. ALT or AST \\>400 IU\u002FL\n  9. Pulse pressure \\\u003C20mmHg or hypotension for age AND at least one of: peripheral capillary refill time \\>2 seconds; urine output 0.5ml\u002Fkg\u002Fhr; cold\u002Fclammy peripheries; agitation or altered mental state\n  10. Bleeding leading to hypotension for age or requiring blood transfusion or medical intervention (e.g. surgery, endoscopy, or vasoactive drugs)\n  11. Symptomatic bleeding into a critical site (intracranial, intraspinal, intraocular with visual impairment, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)\n  12. Requirement for organ support, including vasopressors or inotropes, assisted ventilation, dialysis or haemofiltration, or coma (unresponsive to pain without sedation) or requirement for intravenous antiseizure medications\n\nExclusion Criteria:\n\n* Patients on ≥ day 10 of illness or who are clinically improving in the opinion of the managing doctor (the 'recovery phase') will be excluded from recruitment. Other exclusion criteria are specific to individual treatment comparisons, and do not preclude randomisation to other arms of the study.\n* A participant may not enter a specific treatment comparison if that treatment is considered to be indicated or contraindicated by the responsible clinician.","ALL","5 Years",{"count":407,"type":408},8800,"ESTIMATED","INTERVENTIONAL",[411],"PHASE3","The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.",[414,415,416,417,418,419,420,421],"Dengue","Severe Dengue","Mosquito-Borne Diseases","Vector Borne Diseases","Arbovirus Infections","Flavivirus Infections","RNA Virus Infections","Hemorrhagic Fever",[423,424,425],"dengue treatment","host-directed therapy","host-targeted therapeutics","NOT_YET_RECRUITING","2026-04-15",{"date":429,"type":430},"2026-04-21","ACTUAL",{"date":432,"type":408},"2026-10-01",{"date":434,"type":408},"2031-07-31",{"name":5,"class":6},18]